Ophthalmology – Retinitis Pigmentosa

Ophthalmology – Retinitis Pigmentosa

What Retinitis Pigmentosa Represents

Retinitis pigmentosa (RP) refers to a genetically heterogeneous group of inherited retinal dystrophies characterized predominantly by progressive dysfunction and loss of:

Rod photoreceptors first
Followed by secondary cone degeneration

For this reason, many specialists also use the term:

Inherited rod-cone dystrophy

The typical sequence is:

Nyctalopia → progressive midperipheral field loss → tunnel vision → eventual central vision impairment

The rate and severity of progression vary widely according to:

Causative gene
Specific pathogenic variant
Mode of inheritance
Associated systemic disease

How Common It Is

RP is among the most common inherited retinal degenerations.

Estimated prevalence is approximately:

1 in 3,000–5,000 people

although prevalence varies among populations.

Why the Retina Degenerates

In classic RP, the primary abnormality involves:

Rod photoreceptors

Rod loss initially produces:

Night blindness
Midperipheral visual field loss

Secondary degeneration then affects:

Cone photoreceptors

causing later:

Reduced central acuity
Reduced color vision
Photophobia
Loss of reading vision

Pattern of Retinal Involvement

Degeneration classically begins in the:

Midperipheral retina

and gradually spreads:

Peripherally
Centrally toward the macula

This explains the characteristic early ring or annular field defect.

Inheritance and Molecular Basis

RP is one of the most genetically diverse ophthalmic disorders.

Inheritance may be:

Autosomal dominant
Autosomal recessive
X-linked
Mitochondrial in selected syndromes
Sporadic/de novo

A substantial proportion of apparently isolated cases can now be molecularly diagnosed using modern genetic testing.

Important RP Genes

Many dozens of genes can cause nonsyndromic RP.

Common examples include:

RHO
RPGR
USH2A
EYS
PRPF31
PDE6A
PDE6B
CNGB1
RPE65
RP1

The relative frequency varies substantially by:

Population
Inheritance pattern
Ancestry

Autosomal Dominant RP

Frequently associated genes include:

RHO
PRPF31
RP1

Autosomal dominant disease often has:

Later onset
Slower progression

than severe X-linked forms, although phenotype varies greatly.

Autosomal Recessive RP

Autosomal recessive RP is genetically very heterogeneous.

Important genes include:

USH2A
EYS
PDE6A
PDE6B
RPE65

Consanguinity can increase the likelihood of recessive disease.

X-Linked RP

A major cause of X-linked RP is:

RPGR

X-linked RP often causes:

Early nyctalopia
Rapid peripheral field loss
Earlier central visual decline

Affected males tend to have more severe disease.

Female carriers may show:

Normal fundus
Patchy pigmentary changes
Radial autofluorescence pattern
Occasionally significant visual dysfunction

because of variable X-chromosome inactivation.

Variable Expression

Even relatives carrying the same pathogenic variant may show:

Different age of onset
Different rates of progression
Different degrees of central vision preservation

Thus:

Genotype helps with prognosis but does not perfectly predict phenotype.

Isolated vs Syndromic Disease

RP may occur as:

Nonsyndromic RP
Part of a multisystem inherited disorder

Recognizing syndromic disease is important because associated systemic abnormalities may require treatment or surveillance.

Usher Syndrome

The most important syndromic association is:

Usher syndrome

characterized by combinations of:

RP
Sensorineural hearing loss
Vestibular dysfunction in some subtypes

Different subtypes have different:

Hearing severity
Vestibular involvement
Age of retinal symptom onset

Patients with RP should be asked specifically about:

Hearing impairment.

Bardet-Biedl Syndrome

Features may include:

Rod-cone dystrophy
Obesity
Postaxial polydactyly
Renal disease
Hypogonadism
Developmental or learning difficulties

The renal component can be medically significant.

Refsum Disease

A particularly important treatable association is:

Adult Refsum disease

which may cause:

RP
Peripheral neuropathy
Cerebellar ataxia
Hearing loss
Anosmia
Ichthyosis

It results from impaired phytanic acid metabolism.

Unlike most RP:

Dietary treatment and plasmapheresis in selected cases can modify systemic disease, making diagnosis clinically important.

Other Syndromic Associations

RP-like retinal degeneration can occur in:

Alström syndrome
Senior-Løken syndrome
Joubert-spectrum disorders
Mitochondrial disorders
Peroxisomal disorders
Some ciliopathies

Systemic history should therefore be part of the retinal assessment.

Earliest Symptom

The classic first symptom is:

Nyctalopia

or difficulty seeing in dim illumination.

Patients may describe:

Difficulty entering a dark cinema
Trouble walking outdoors at night
Difficulty driving at dusk
Slow dark adaptation

Progression of Visual Field Loss

Field loss typically begins as:

Patchy midperipheral scotomas

These gradually enlarge and merge into:

A ring scotoma

Further progression produces:

Tunnel vision

with a residual central island.

Some patients retain a far peripheral temporal island as well.

Central Vision

Central acuity can remain relatively good for:

Many years or decades

because foveal cones may initially be preserved.

Later central loss can result from:

Cone degeneration
Cystoid macular edema
Epiretinal membrane
Macular atrophy
Cataract

Photopsias

Patients may experience:

Flashing lights
Shimmering
Sparkling sensations

These photopsias are common in inherited retinal degeneration and do not necessarily indicate retinal tear.

However, a new acute change in flashes/floaters still warrants appropriate retinal evaluation.

Photophobia

Cone dysfunction and altered retinal adaptation may cause:

Glare
Photophobia
Difficulty in bright diffuse light

Tinted lenses may improve comfort but:

Have not been proven to slow retinal degeneration.

Characteristic Fundus Triad

The classic triad consists of:

Bone-spicule pigmentation
Attenuated retinal arterioles
Waxy pallor of the optic disc

This triad is highly characteristic of established RP.

Bone-Spicule Pigmentation

Bone-spicule pigmentation results from:

RPE cell migration into the inner retina

following photoreceptor degeneration.

The pigment often accumulates around:

Retinal vessels
Midperipheral retina

Vascular Attenuation

Retinal vessels become progressively:

Narrow
Attenuated

reflecting reduced metabolic demand and retinal degeneration.

Waxy Optic Disc Pallor

The optic disc may develop a characteristic:

Waxy yellow-pale appearance

related to:

Axonal loss
Gliosis
Chronic retinal degeneration

Early Disease May Lack Pigment

Some patients with genetically confirmed RP have little or no bone-spicule pigmentation early in the disease.

This has historically been called:

RP sine pigmento

The diagnosis then depends more heavily on:

Symptoms
ERG
OCT
FAF
Genetic testing

Sector RP

Sector retinitis pigmentosa is a milder phenotype in which retinal degeneration is limited mainly to:

One or two quadrants

It is often:

Inferior retinal

producing corresponding superior field defects.

It may remain relatively stable for long periods in some patients.

Lens Changes

A common anterior segment association is:

Posterior subcapsular cataract

It may develop earlier than typical age-related cataract and contribute substantially to:

Glare
Reduced contrast
Central visual loss

Vitreous Findings

Patients may have:

Mild vitreous cells
Vitreous degeneration

Low-grade vitreous cells alone do not imply infectious or inflammatory uveitis.

Macular Complications

Important causes of central vision loss include:

Cystoid macular edema
Epiretinal membrane
Vitreomacular traction
Macular atrophy

Cystoid Macular Edema

RP-associated CME can occur even in advanced peripheral degeneration.

Patients may notice:

Blurred central vision
Reduced reading ability
Metamorphopsia

OCT is the preferred test.

Establishing the Diagnosis

Diagnosis combines:

Clinical history
Dilated examination
Full-field electroretinography
Visual field testing
OCT
Fundus autofluorescence
Genetic testing

No single test should be interpreted in isolation.

Full-Field Electroretinography

Full-field ERG is a key physiologic test for generalized rod-cone dysfunction.

Typical RP demonstrates:

Markedly reduced rod responses
Later reduced cone responses
Reduced a-wave and b-wave amplitudes
Delayed implicit times

Rod dysfunction is usually disproportionately severe early.

Advanced ERG Changes

In late-stage RP:

Full-field ERG may become nonrecordable

even while a small central island of useful visual function remains.

Thus ERG amplitude does not equal central visual acuity.

Optical Coherence Tomography

Macular OCT is essential in modern RP assessment.

It evaluates:

Outer retinal integrity
Ellipsoid zone
External limiting membrane
Outer nuclear layer
Macular atrophy
CME
Epiretinal membrane

Ellipsoid Zone

The width of the preserved:

Ellipsoid zone (EZ)

is a useful structural marker of remaining photoreceptor integrity.

Serial EZ measurements can help assess:

Disease progression.

Fundus Autofluorescence

FAF commonly demonstrates:

Peripheral hypoautofluorescence from RPE loss
Areas of mottled abnormal autofluorescence
A characteristic hyperautofluorescent parafoveal ring

Hyperautofluorescent Ring

A parafoveal hyperautofluorescent ring often marks the transition between:

Relatively preserved central retina
More dysfunctional peripheral retina

The ring may constrict over time as disease progresses.

Visual Field Assessment

Visual fields document functional progression.

Useful approaches include:

Automated static perimetry
Kinetic perimetry, especially for extensive peripheral loss

Kinetic testing can be particularly useful in advanced disease because it maps:

Remaining peripheral islands
Central residual field

Color Vision

Color vision may remain relatively preserved early.

With advanced cone involvement, patients may develop:

Generalized dyschromatopsia
Blue-yellow abnormalities

Dark Adaptation

Dark adaptation testing may show:

Prolonged rod adaptation
Markedly impaired scotopic sensitivity

It is useful in specialized inherited retinal disease assessment but is not mandatory for every patient.

Genetic Testing

Modern management increasingly includes:

Molecular genetic testing

usually with:

Inherited retinal disease multigene panel
Exome/genome sequencing when necessary

Testing can:

Confirm diagnosis
Establish inheritance pattern
Clarify recurrence risk
Identify syndromic disease
Determine eligibility for gene-specific therapies or trials

Genetic Counseling

Genetic counseling is important both:

Before and after testing

because results may have implications for:

Siblings
Parents
Children
Reproductive planning
Systemic screening

Important Diagnostic Alternatives

Conditions that can mimic RP include:

Congenital stationary night blindness
Leber congenital amaurosis / early-onset severe retinal dystrophy
Fundus albipunctatus
Choroideremia
Gyrate atrophy
Vitamin A deficiency
Autoimmune retinopathy
Cancer-associated retinopathy
Drug toxicity
Congenital infections
Inflammatory retinal disease

RP vs Congenital Stationary Night Blindness

Progressive
Often pigmentary retinal degeneration
Progressive field loss

Congenital Stationary Night Blindness

Present from childhood
Nonprogressive or minimally progressive
Often relatively normal fundus
Characteristic ERG pattern

Vitamin A Deficiency

Vitamin A deficiency can cause:

Night blindness
Abnormal ERG
Xerophthalmia in severe cases

Unlike genetic RP, it may be:

Reversible with appropriate replacement

after the cause is established.

Medication Toxicity

RP-like pigmentary retinopathy may follow exposure to certain drugs, classically:

Thioridazine

History of medication exposure can therefore be important.

Autoimmune Retinopathy

Autoimmune or cancer-associated retinopathy can cause:

Rapid photoreceptor dysfunction
Photopsias
Visual field loss
Initially subtle fundus findings

The typically:

Rapid onset and progression

help distinguish it from most inherited RP.

Overall Management Strategy

There is currently no universal treatment that stops all forms of RP.

Management focuses on:

Identifying the molecular diagnosis
Treating reversible complications
Providing gene-specific therapy when available
Maximizing remaining vision
Low-vision rehabilitation
Genetic and psychosocial support

Important Modern Correction – Vitamin A

Routine high-dose:

Vitamin A palmitate 15,000 IU/day is no longer generally recommended for RP.

Earlier studies suggested a possible modest benefit, but subsequent reassessment has not established sufficient benefit to justify routine high-dose supplementation, particularly given risks such as:

Hepatotoxicity
Bone effects
Teratogenicity

High-dose vitamin A should therefore:

Not be started routinely for nonspecific RP.

Omega-3 and Lutein

Omega-3 fatty acids and lutein have historically been suggested as supplements.

At present:

They are not established disease-modifying therapies for RP.

Patients should not be told that these supplements reliably slow retinal degeneration.

Vitamin E

Older studies raised concern about high-dose vitamin E supplementation in RP.

There is no reason to use high-dose vitamin E specifically as an RP treatment.

General supplementation should follow:

Nutritional need
Broader medical guidance

rather than an RP-specific protocol.

Gene Therapy

The major advance in inherited retinal disease is:

Gene-specific therapy

rather than a single treatment for all RP.

RPE65 Gene Therapy

Voretigene neparvovec is an approved gene therapy for patients with:

Biallelic pathogenic RPE65 variants and viable retinal cells

It is delivered by:

Subretinal injection

and can improve:

Functional vision
Light sensitivity
Navigation under low illumination

Important Gene-Therapy Principle

Voretigene is:

Not a general treatment for all retinitis pigmentosa.

Patients must have:

Molecularly confirmed biallelic RPE65 disease
Sufficient viable retina

Emerging Molecular Therapies

Clinical trials are evaluating approaches such as:

Gene augmentation
Gene editing
Antisense oligonucleotides
Optogenetics
Neuroprotective strategies

for several inherited retinal dystrophies.

Eligibility depends on:

Specific gene
Disease stage
Residual retinal structure

Stem Cell Approaches

Photoreceptor/RPE cell replacement strategies remain:

Investigational

and are not routine standard treatment for RP.

Patients should be cautious about unregulated commercial “stem-cell” treatments.

Retinal Prostheses

Electronic retinal prostheses have been developed for profound outer retinal degeneration.

However, currently they have:

Very limited routine clinical availability

and older implants such as the Argus II are no longer broadly available as standard therapy.

Treating RP-Associated Macular Edema

First-line treatment commonly involves:

Carbonic anhydrase inhibition

Examples include:

Topical dorzolamide
Topical brinzolamide
Oral acetazolamide

Carbonic Anhydrase Inhibitors

These may:

Reduce cystic retinal spaces
Improve central retinal thickness
Improve acuity in some patients

Response is variable, and:

Rebound edema can occur.

Oral Acetazolamide

Oral acetazolamide can be more effective than topical therapy in some patients but carries systemic adverse effects such as:

Paresthesias
Fatigue
Electrolyte disturbances
Kidney stones
Gastrointestinal symptoms

Long-term treatment should be individualized.

Other CME Treatments

Selected refractory cases may be treated with:

Intravitreal corticosteroids
Periocular steroids
Anti-VEGF in selected circumstances

but evidence is less consistent than for carbonic anhydrase inhibitors.

Cataract Management

Visually significant posterior subcapsular cataract can be treated with:

Phacoemulsification and IOL implantation

Potential benefits can be substantial if:

Foveal photoreceptor structure remains preserved

Cataract Surgery Considerations

Patients with RP may have increased risk of:

Postoperative CME
Capsular contraction
Zonular weakness in some cases
Posterior capsule opacification

Macular OCT before surgery helps estimate visual potential.

Epiretinal Membrane Surgery

Vitrectomy with membrane peeling may occasionally be considered for:

Significant traction
Distortion
Progressive visual loss

but expected benefit depends on residual photoreceptor function.

Photophobia Management

Helpful measures include:

Tinted lenses
Filters
Hats/visors
Individualized lighting

There is no convincing evidence that dark glasses:

Slow RP progression

but they can substantially improve comfort.

Low-Vision Rehabilitation

Low-vision services are an essential part of RP care.

Options include:

Magnifiers
Electronic magnification
Smartphone accessibility tools
Screen readers
High-contrast displays
Orientation and mobility training

Mobility Training

Progressive peripheral field loss can impair:

Navigation
Driving
Stair use
Mobility in dim illumination

Orientation and mobility training can improve:

Safety and independence.

Driving Assessment

Driving ability depends strongly on:

Visual field
Central acuity
Local licensing regulations

Patients with advanced constriction may lose legal driving eligibility despite relatively good central acuity.

Hearing Assessment

Because of the association with:

Usher syndrome

patients with suspected RP should be asked about hearing.

Audiology referral is appropriate when there is:

Hearing difficulty
Early-onset RP
Syndromic suspicion

Systemic Review

Depending on phenotype, ask about:

Hearing loss
Obesity
Polydactyly
Renal disease
Neuropathy
Ataxia
Developmental delay
Anosmia
Cardiac disease

These findings may identify syndromic or treatable disease.

Family Evaluation

Relatives may benefit from:

Clinical examination
Genetic counseling
Targeted molecular testing after a familial variant is identified

Routine examination alone may miss:

Female X-linked carriers
Presymptomatic disease

so genetic information can be particularly useful.

Pregnancy and Reproductive Planning

Patients with a molecular diagnosis may receive counseling regarding:

Recurrence risk
Carrier testing
Prenatal diagnosis
Preimplantation genetic testing

These are personal reproductive choices guided by:

The specific inheritance pattern and family preferences.

Monitoring Over Time

Follow-up is individualized, often approximately:

Every 6–12 months

for stable disease.

Assess:

Visual acuity
Symptoms
Visual fields
OCT
FAF
Cataract
CME

ERG does not necessarily need to be repeated at every routine visit.

Measuring Progression

Useful longitudinal biomarkers include:

Visual field area
Ellipsoid-zone width
Fundus autofluorescence ring diameter
Central retinal structure
Best-corrected visual acuity

These often provide more practical progression information than repeated full-field ERG alone.

Expected Course

RP is generally:

Progressive

but the rate varies dramatically.

Some patients:

Retain useful central vision into late adulthood

while others develop:

Severe visual disability much earlier

Prognostic Clues

Prognosis depends on:

Causative gene
Mutation type
Inheritance pattern
Age of onset
Rate of field loss
Ellipsoid-zone preservation

X-linked RP is often among the more severe forms.

Causes of Late Central Vision Loss

Central vision may decline because of:

Cone degeneration
Cystoid macular edema
Macular atrophy
Epiretinal membrane
Posterior subcapsular cataract

Some of these are treatable, so new central visual loss should not automatically be attributed to inevitable RP progression.

Possible Complications

Important associated problems include:

Cystoid macular edema
Posterior subcapsular cataract
Epiretinal membrane
Vitreomacular traction
Progressive field constriction
Central macular atrophy
Severe visual disability

Ophthalmology Pearls

Retinitis pigmentosa is a genetically heterogeneous inherited rod-cone dystrophy characterized by progressive rod loss followed by secondary cone degeneration.
The classic clinical sequence is nyctalopia → midperipheral ring scotoma → tunnel vision → eventual central visual loss.
The classic fundus triad is bone-spicule pigmentation, attenuated retinal arterioles, and waxy optic disc pallor.
Bone-spicule pigment represents migration of RPE cells into the inner retina following photoreceptor degeneration.
Early RP can have little or no pigment, historically termed RP sine pigmento.
Full-field ERG demonstrates generalized rod-cone dysfunction and remains an important diagnostic test.
OCT and fundus autofluorescence are central modern monitoring tools, especially ellipsoid-zone preservation and the hyperautofluorescent parafoveal ring.
Modern genetic testing should be strongly considered, because it can establish inheritance, identify syndromic disease, guide counseling, and determine eligibility for gene-specific therapies.
Always ask about hearing loss, because RP plus sensorineural deafness strongly suggests Usher syndrome.
Obesity, polydactyly, renal dysfunction, and retinal degeneration suggest Bardet-Biedl syndrome.
Neuropathy, ataxia, anosmia, and ichthyosis with RP should raise suspicion for Refsum disease, an important potentially treatable systemic disorder.
Routine high-dose vitamin A palmitate is no longer recommended as standard RP therapy.
Omega-3 fatty acids and lutein are not established disease-modifying treatments for RP.
Voretigene neparvovec is a gene-specific treatment for biallelic RPE65-associated inherited retinal dystrophy, not for RP in general.
RP-associated cystoid macular edema is commonly treated first with topical or oral carbonic anhydrase inhibitors.
Posterior subcapsular cataract is common and may be surgically treatable, so reduced vision should not automatically be attributed solely to photoreceptor degeneration.
Dark or tinted glasses may improve photophobia, but they have not been shown convincingly to slow retinal degeneration.
Low-vision rehabilitation, orientation and mobility training, genetic counseling, and psychosocial support are major components of long-term care.
New central visual deterioration should prompt evaluation for CME, cataract, epiretinal membrane, or other treatable complications, rather than simply assuming progression of RP.

Ophthalmology – Retinitis Pigmentosa

Kembara Xtra

Archives

Categories